Proteomics International Laboratories (ASX:PIQ) investors are left with "considerable unknowns" after the medical technology business terminated its exclusive license with Sonic Healthcare USA for its PromarkerD kidney disease diagnostic tool, according to a Wednesday note from Euroz Hartleys.
The license was canceled after certain milestones were not met, with the US launch now slated for 2025, targeting alternative pathology labs and service providers, and direct to consumers and patients.
While Proteomics has partners for Europe and other territories for PromarkerD, not commercializing in the US healthcare market, the world's largest, has lost potentially 32 million patients and potential users of the test, the investment firm said.
Euroz Hartleys downgraded Proteomics to hold from speculative buy and lowered the price target to AU$0.73 price target from AU$1.10 on increased uncertainties around the commercialization of PromarkerD in the US.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.